American Journal of Clinical Pathology · 2002 · 142 citations · 21 references
MedicineOncologyPathologyHistopathologyMetastasisNeoplasiaCancer BiomarkersImmunohistochemistryProstate CancerProstate PathologyProstatic PathologyTumor MarkersGleason ScoringProstate Cancer DiagnosisProstate HistologyProstate Tumor MarkersProstatic AdenocarcinomaProstatic BiomarkersProstatic Intraepithelial Neoplasia GradingStaining Characteristics
This study provides detailed staining results for 225 prostate adenocarcinomas, including 150 Gleason score 8, 9, and 10 adenocarcinomas with cytokeratins (CKs) 7, 20, 5/6, and 17, prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), carcinoembryonic antigen (CEA), WT1, thyroid transcription factor-1 (TTF-1), and villin. CK7 was reactive in 112 adenocarcinomas (49.8%). The percentage of CK7-reactive adenocarcinomas and the percentage of CK7-stained cells increased in higher Gleason score adenocarcinomas; most reactive neoplasms had CK7 staining of fewer than 25% of cells. CK20 had similar results. The percentage of PSA- and PAP-reactive adenocarcinomas and the percentage of stained cells in reactive neoplasms decreased in higher Gleason score adenocarcinomas. CK5/6 and CK17, WT1, CA-125, TTF-1, and villin were nonreactive. The prostate can be the primary site of metastatic adenocarcinoma that is nonreactive for PAP and PSA and has CK7 or CK20 reactivity in fewer than 50% of the cells. The likelihood that a metastatic adenocarcinoma is from the prostate is low if reactivity with any of the cytokeratin antibodies, CEA, TTF-1, CA-125, WT1, or villin is extensive.
21
Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas.
P.A. Bejarano, Robert P. Baughman, Paul W. Biddinger et al. · PubMed · 1996 · 230 citations
Nelson G. Ordóǹez · The American Journal of Surgical Pathology · 2000 · 222 citations